Evanescent Prostate Carcinoma, Case Report

ABSTRACT

Objective: To report the treatment and clinical monitoring in patients with prostatic evanescent carcinoma at Hospital Carlos Andrade Marin. Methods: We reviewed the medical records of 148 patients undergoing by robot-assisted radical prostatectomy in Carlos Andrade Marin hospital. The cases reported between January 2016 to December 2018. The diagnosis was carried by taking a transrectal prostate biopsy with 12 cylinders. This samples are studied by the pathologist who reviews the radical prostatectomy surgery. Results: Three patients had prostatic evanescent carcinoma, which those cases showed Gleason 6 (3+3) prostate cancer. Two received neoadjuvant hormone therapy and the other patient presented minor tumor invasion in 1 out of 12 cylinders used during the biopsy. In the three cases, after the sample analysis, there was no residual tumor evidence. Therefore, they were classified as pT10. Conclusions: In this study, the results obtained from the patients studied presents the incidence of prostatic evanescent carcinoma is 2%. The combination of these different factors such as clinical status, preoperative PSA, number of positive cylinders and the invasion percentage, additionally to the usage of neoadjuvant hormone therapy prior the radical prostatectomy can help to predict evanescent carcinoma of the prostate (AU)

RESUMEN

Objetivos: Reportar la experiencia del Hospital Carlos Andrade Marín en el tratamiento y seguimiento de pacientes con cáncer de próstata evanescente.Materiales y Métodos: Se ha estudiado las historiasclínicas de 148 pacientes que se realizaron prostatectomíaradical asistida por robot en el Hospital Carlos AndradeMarín en el periodo enero 2016 hasta diciembre 2018, eldiagnostico se realiza mediante toma de biopsia prostáticatransrectal con toma de 12 cilindros, los cuales son estudiados por el mismo medico patólogo que revisa la piezaquirúrgica de prostatectomía radical.Resultados: Se identifican tres casos de carcinomade próstata evanescente, los cuales presentan carcinoma depróstata Gleason 6 (3+3), dos reciben terapia neoadyuvantehormonal y uno presenta escasa invasión tumoral en 1/12cilindros de biopsia prostática (cáncer de próstata diminuto). En los tres casos después del análisis de las piezasquirúrgicas no se evidencia tumor residual por lo que se loscataloga como pT0.Conclusiones: En nuestra experiencia la incidenciade carcinoma de próstata evanescente es del 2% en elgrupo de pacientes estudiados. La combinación del estadio clínico, PSA preoperatorio, numero de cilindros positivos y el porcentaje de invasión de los mismos como el usode neoadyuvancia previo a la prostatectomía radical puedeayudar a predecir el fenómeno de carcinoma de próstata evanescente (AU)